Indian pharmaceutical stocks, including Lupin, Shilpa Medicare, and Natco Pharma, are under scrutiny following recent USFDA inspections at their manufacturing sites. These audits yielded regulatory observations, prompting companies to address the findings. Alkem Laboratories, however, reported no critical issues from a separate Armenian health ministry audit at its Sikkim facility.
Source link
Natco Pharma, 3 other pharma stocks decline up to 2.5% after important inspections at their units. Do you own?
